NCT01863108View on ClinicalTrials.gov

Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 23, 2017

Study Completion Date

March 23, 2017

Conditions
MelanomaTumor VaccinesEffects of Immunotherapy
Interventions
BIOLOGICAL

GeniusVac-Mel4

Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma

Trial Locations (1)

38000

Grenoble University Hospital, Grenoble

All Listed Sponsors
collaborator

Etablissement Français du Sang

OTHER

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Université Joseph Fourier

OTHER

lead

University Hospital, Grenoble

OTHER

NCT01863108 - Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma | Biotech Hunter | Biotech Hunter